How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2125-2126

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; INTERFERON; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE;

DATA ANALYSIS; EDITORIAL; HUMAN; KIDNEY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; EVIDENCE BASED MEDICINE; KIDNEY TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MORTALITY; NOTE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RESEARCH DESIGN; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952310527     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4951     Document Type: Editorial

References (11)

1. Hainsworth JD, Spigel DR, Burris HA III, et al: Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136, 2010
2. Whorf RC, Hainsworth JD, Spigel DR, et al: Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26:252s, 2008 (suppl; abstr 5010)
3. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
4. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
5. Motzer R, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
6. Sternberg C, Szczylik C, Lee E, et al: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27:240s, 2009 (suppl; abstr 5021)
7. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer (in press)
8. Daliani DD, Papandreou CN, Thall PF, et al: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765, 2002 (Pubitemid 34839667)
9. Hainsworth JD, Sosman JA, Spigel DR, et al: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896, 2005 (Pubitemid 46657387)
10. Bukowski RM, Kabbinavar FF, Figlin RA, et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536-4541, 2007 (Pubitemid 350035309)
11. Merchan JR, Liu G, Fitch T, et al: Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol 25:243s, 2007 (suppl; abstr 5034)